Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial
- Conditions
- Lymphatic DiseasesChylothorax
- Interventions
- Drug: Saline infusion
- Registration Number
- NCT05683444
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
This study aims to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. To study the effects of octreotide, the researchers conducted a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and other lymphatic disorders.
- Detailed Description
This study aimed to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. Chylothorax is a condition in which there is an accumulation of lymphatic fluid in the chest cavity, and the mechanism through which octreotide helps to resolve this condition is not well understood. It has been speculated that the drug may reduce lymph production, but this has not been directly demonstrated. To study the effects of octreotide on human lymphatic vessels, the investigators conducted two experiments: a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber, and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults, assessed by using plethysmography and near-infrared fluorescence imaging. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and to clarify the mechanism through which it acts. It is important to continue researching and developing effective treatments for chylothorax, as it can be a difficult condition to manage and may cause serious complications if left untreated.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
* Healthy
- No daily medication (except birth control), or allergies towards contrast agents.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Healthy participant 1 Saline infusion - Healthy participant 1 Octreotide infusion - Healthy participant 2 Octreotide infusion - Healthy participant 2 Saline infusion -
- Primary Outcome Measures
Name Time Method Lymph Pressure During infusion mmHg assessed by near-infra fluorescence imaging
Isovolumetric pressure During infusion assessed by plethysmography
Capillary filtration rate During infusion assessed by plethysmography
Capillary filtration coefficiency During infusion assessed by plethysmography
Lymph rate During infusion Propulsions /minute
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Rigshospitalet
🇩🇰København Ø, Denmark